Enlicitide Lowers LDL-C in Patients With Kidney Disease

New trial data shows significant cholesterol reduction for patients with impaired kidney function.

Updated on Oct. 24, 2026 in Heart Disease

Enlicitide Lowers LDL-C in Patients With Kidney Disease

Live Poll

Should medical studies be required to include specific data for patients with pre-existing kidney disease?

Pooled data from the CORALreef trial demonstrates that the daily medication enlicitide effectively reduces LDL-C in patients with reduced kidney function. Patients with an eGFR below 60 saw a 65.9% placebo-adjusted LDL-C reduction by week 24.

Why it matters

Individuals with reduced kidney function face significantly elevated cardiovascular risks and frequently struggle to reach standard lipid targets. This data suggests enlicitide could be a viable option for managing cholesterol in this vulnerable population.

A pooled analysis of 3,212 participants showed that 80.5% of enlicitide-treated patients with eGFR below 60 achieved an LDL-C below 70 mg/dL by week 24. Research indicates that taking the 20 mg tablet after a meal reduces steady-state exposure by 48%.

The details

Researchers presented findings at Kidney Week 2026 showing that enlicitide maintains a safety profile comparable to a placebo in patients with impaired kidney function. The medication must be taken in the morning on an empty stomach with water, black coffee, or plain tea, with a 30-minute wait before eating.

July 2026: The FDA approved enlicitide 20 mg once daily.
October 2026: Data was presented at Kidney Week 2026 in Denver.
Week 24: Placebo-adjusted LDL-C reduction was measured during the study.
Week 52: Adverse events and LDL-C changes were assessed in the long-term analysis.

The Big Picture

This analysis extends the ongoing findings of the larger CORALreef Outcomes trial by highlighting specific efficacy in the renal-impaired sub-group. The 14,500-participant trial is currently investigating whether this lipid-lowering therapy reduces cardiovascular morbidity and mortality.

Patients prescribed enlicitide must strictly adhere to morning dosing on an empty stomach to ensure medication effectiveness, as food intake can significantly reduce drug exposure. Consult with a healthcare provider to determine if this treatment is appropriate for your specific kidney function and cardiovascular profile.

The takeaway

Patients should note that taking enlicitide after a meal can reduce its efficacy by nearly half, making strict adherence to morning fasting protocols essential. Consistent monitoring is recommended as researchers continue to evaluate the long-term cardiovascular benefits of this treatment.